Interés Humano

EE. UU. emite autorización de emergencia para vacuna de Pfizer/BioNTech contra covid-19

El presidente Trump inmediatamente dijo que la primera vacuna será administrada “en menos de 24 horas”, en un video publicado en Twitter.

(FILES) In this file photo illustration taken on November 23, 2020, shows a syringe and a bottle reading "Covid-19 Vaccine" next to the Pfizer company logo. - The vaccine advisory committee of the US Food and Drug Administration (FDA) will meet December 10, 2020 after poring over data from clinical trials carried out by Pfizer/BioNTech.
The FDA should then give its authorization for emergency use of the vaccine. That decision could come "within days after the advisory committee" meets, Health Secretary Alex Azar said.
On December 17, the same process will unfold for the Moderna vaccine. (Photo by JOEL SAGET / AFP)
(FILES) In this file photo illustration taken on November 23, 2020, shows a syringe and a bottle reading "Covid-19 Vaccine" next to the Pfizer company logo. - The vaccine advisory committee of the US Food and Drug Administration (FDA) will meet December 10, 2020 after poring over data from clinical trials carried out by Pfizer/BioNTech. The FDA should then give its authorization for emergency use of the vaccine. That decision could come "within days after the advisory committee" meets, Health Secretary Alex Azar said. On December 17, the same process will unfold for the Moderna vaccine. (Photo by JOEL SAGET / AFP) JOEL SAGET
Se espera que la próxima semana unas 2,9 millones de dosis comiencen a aplicarse en Estados Unidos, país que registra 290.000 muertes por covid-19. Foto: AFP (JOEL SAGET/AFP)

Autoridades sanitarias de Estados Unidos otorgaron el viernes una autorización de emergencia a la vacuna de Pfizer-BioNTech contra la covid-19, allanando el camino a su distribución en el país, con la promesa del presidente Donald Trump de que la primera vacunación empezará en “menos de 24 horas”.

“Estoy autorizando el uso de emergencia de la vacuna de covid-19 de Pfizer-BioNTech”, escribió Denise Hinton, directora científica de la Administración de Alimentos y Medicamentos (FDA), en una carta a un ejecutivo de Pfizer.

‌
‌

‌

‌
‌

‌

‌